| The Effect of Tumor Size on Oncologic Outcomes in Pathological T2 Stage Renal Cell Carcinoma Patients | Nurullah HAMİDİ,EVREN SÜER,MEHMET İLKER GÖKCE,MEHMET YAŞAR BEDÜK,SÜMER BALTACI | 1–3 |
| Do the Pain Scores During Transrectal Ultrasound-guided Prostate Rebiopsy Change in Patients with a Prior History of Prostate Biopsy? | Deniz BOLAT,Mehmet Erhan AYDIN,BÜLENT GÜNLÜSOY,TANSU DEĞİRMENCİ,Yusuf Kadir TOPÇU,İbrahim KÜÇÜKTÜRKMEN,Zafer KOZACIOĞLU | 4–7 |
| Kanserin Rengi Nedir? | Volkan TATLI MD,Oktay ÜÇER MD,Talha MÜEZZİNOĞLU MD | 8–11 |
| Social Awareness on Early Diagnosis and Treatment of Bladder Cancer: Importance of Age and Education | Doğan DEĞER,Öner Deniz ASLAN,Kaan ÇÖMEZ,Feyzullah EREN,Sedik ADIRBELLİ,GÜVEN ASLAN | 12–16 |
| The Relationship between Bladder Cancer and Epigenetic Alterations | ATA ÖZEN,Ali ÜLGEN,YUNUS SAİM CAVİT CAN | 17–21 |
| Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers? | ECE KONAÇ,Sinan SÖZEN | 22–27 |
| Incidentally Found Paratesticular Rhabdomyosarcoma: Case Report | Halil Çağrı AYBAL,Taha Numan YIKILMAZ,Fatih HIZLI,Halil BAŞAR,Emin Taha KESKİN | 28–30 |
| A Rare Tumor: Prostate Neuroendocrine Carcinoma Case Report | Eşref Oğuz GÜVEN,Numan YIKILMAZ,Erdem ÖZTÜRK,Erman DAMAR,Halil BAŞAR | 31–33 |